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The  prophylactic  immunization  of  man  against  bacillary  dysentery  has 
proved to be a  difficult  problem.  The  severe reactions evoked by the toxic 
microorganisms  used  in  vaccines  (1,  2),  the  multiplicity  of  bacterial  types 
encountered in the disease,  and  the difficulties  experienced in evaluating the 
efficacy of vaccines are all factors which have impeded progress in the control 
of the disease by immunological  measures. 
During the past year we have been engaged in a study of the specific antigens 
of the Flexner group of dysentery microorganisms.  Our purpose has been to 
learn something of the chemical  nature of these substances and something of 
their  immunological  and  toxic properties  as  well.  The  specific  antigens  of 
the Flexner organisms  are lipocarbohydrate-protein complexes similar  to those 
isolated  by  other  investigators  from  various  Gram-negative  bacilli  (3-5). 
These substances appear  to reflect the essential imrnunological  properties of 
the microorganisms from which they are  derived.  They are  toxic and  give 
rise  in  experimental  animals  to  antisera  which  agglutinate  the  homologous 
organism,  precipitate the antigen, and confer passive protection on mice against 
lethal infections. 
Numerous  attempts  have  been  made  to  modify or  detoxify vaccines  of 
dysentery  bacilli  for  purposes  of  prophylactic  immunization,  but  thus  far 
this has not been satisfactorily achieved (2, 6-11).  In an effort to avoid the 
toxic reactions evoked by the injection of certain  Gram-negative  organisms, 
other  investigators  have  separated  the  O  antigens  from extraneous  cellular 
elements  and  have  used  these  substances  experimentally  in  man  (12,  13). 
Because organisms  of the Shigella  paradysenteriae  (Flexner)  group are  those 
most frequently encountered in areas where bacillary dysentery is prevalent 
(14-21) and because of the difficulties experienced  with the use of whole bacte- 
rial vaccines, we have studied the response in man to the injection of the specific 
antigen of the Type V organism.  The antigen of this type cross-reacts with 
other organisms of the group and was, therefore, chosen in the present study. 
* The work described in this paper was done under contract, recommended by  the Com- 
mittee on  Medical Research, between  the Office of Scientific  Research and Development 
and The Rockefeller Institute for Medical Research. 
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That  this  highly  purified  substance  when  administered  intracutaneously  in 
appropriate amounts gives rise to demonstrable circulating antibody in human 
beings without causing severe reactions is seen in the following account. 
EXPERIMENTAL 
Specific, Antlgens.--The  specific antigen and the polysaccharide used in this study  were 
isolated from an acetone-killed  culture of a strain of Shigella paradysenteriae (Flexner) Type V 
obtained from the collection of the Army Medical Center.  The preparation and purification 
of these substances have been described in Paper I of this series. 
The antigen was dissolved in pyrogen-free physiological  saline and sterilized by filtration 
through a Berkefeld candle. 
Injection of tke Antigen.--A group of 19 healthy adult individuals who gave no past history 
of bacillary dysentery was divided into 3 groups, each of which received the indicated doses 
of the antigen intracutaneously at weekly intervals. 
Group I:  Group II:  Group III: 
5  subjects  8  subjects  6 subjects 
Dose  5.0  ug.  2.5  ~g.  Prolonged  course 
7.5  "  7.5  "  (See text) 
10.0  "  15.0  " 
Total ..............  22.5 ug.  25.0 ~g.  40 to 100 ~g. 
The subjects were bled before and 3 weeks following the course of injections. 
All  the volunteers developed a  local reaction following  the  administration 
of the antigen.  The reaction consisted of erythema, swelling, and tenderness 
which appeared in about 4 hours, reached a maximum of 4  X  6 cm. in 18 hours, 
and  completely subsided  in  36  hours.  The  reaction  in  4  of  the  subjects in 
group I and in 5 of the subjects in group II was associated with a lymphangitis 
and  an  epitrochlear  and  axillary  adenopathy.  In  the  entire  group  10 
individuals received an initial dose of 5  /zg. or over, and  9  received an initial 
dose of 2.5/zg.  Four  of the  former and  only one  of the  latter  in  this  group 
developed  a  generalized  systemic  reaction,  consisting  of  malaise,  occipital 
headache,  and  in  some  instances  chills  and  fever.  The  systemic  reactions 
followed the first injection only.  In every case the local reaction became less 
severe  on  subsequent  inoculations  in  spite  of  the  increasing  dose  (22,  23). 
Each  of  the  subjects  in  group  III received  a  somewhat  different  course  of 
injections with the total doses varying from 40 to 100 #g.  No subject in group 
III received a single dose greater than 25 #g. since this seemed to be the greatest 
amount  that  could  be  tolerated  without  systemic  reactions.  After  3  or  4 
injections, 4 of the subjects in group III developed an immediate  allergic type 
of  reaction  (24)  consisting  of  a  wheal  with  pseudopods  and  a  surrounding 
erythematons  flare.  This  reaction  subsided  in  20  to  30  minutes  and  was 
followed by the usual type of reaction.  This allergic response could be avoided 
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Homologous  Agglutinins.--Preliminary  tests  indicated  that  the  maximum 
response  as  measured  in  terms  of  homologous  agglutinins  occurred  2  to  3 
weeks  following  the  last  injection.  Accordingly,  all  the  individuals  were 
bled 3  weeks following the last dose. 
The sera of each individual obtained before and after the course of injections were titrated 
in parallel.  A standardized  suspension of formol-killed Type V organisms was prepared. 
Serial dilutions of serum were mixed with  the bacterial  suspension and incubated at 56°C. 
for 3 hours, then placed in the icebox overnight. 
The titration of 3 sera, an excellent, an average, and a poor serum, is shown 
in Table I.  Here it is seen that in each instance following the course of injec- 
A gglutinln 
TABLE I 
Titration of Serum  of Three Subjects bbfore and  after Inoc,dation with Specific 
Antigen  of Type  V  Shigella paradysenteriae (Flexner) 
Subject 
La 
Go 
Ho 
I 
Serum 
i 
i 
i Pre-treatment 
~ Post-treatment 
Pre-treatment 
i Post-treatment 
Pre-treatment 
Post-treatment  i 
*4== 
½ffi 
0F 
These 
Final dilution of serum 
1:12.5 
2* 
4 
complete agglutination  wit] 
1:25  1:50  1:100  1:200 
1  0  0  0 
4  4  4  4 
½  o  o  o 
4  4  3  1 
3  2  0  0 
4  4  2  0 
clear supernatant liquid. 
agglutination  detectable  with hand lens. 
no agglutination. 
notations are used in all subsequent  tables. 
1:400  1:800 
Increase in 
agglutlnins 
1:1600 
0  32-fold 
0 
0  8-fold 
0 
0  2-fold 
0 
tions  a  definite  increase  in  specific  bacterial  agglutinins  resulted.  Table  II 
summarizes  the  titrations  of  the  sera  of all  the  subjects  and  indicates  the 
average increase for each group.  The subjects in group I  showed an average 
increase of fivefold and those in groups II and III of approximately sixteenfold 
in bacterial agglutinins. 
The prolonged  course  of injections  given  to  the  subjects  in group III was 
not accompanied by a  further increase  in the agglutinin response.  The titer 
of the  sera  of these individuals  reached a  plateau,  and  subsequent  injections 
apparently failed  to increase  the amount of circulating antibody. 
Heterologous  Agglutinins.--The  serum  of  each  individual  was, tested  for 
agglutinins  against  the  heterologous types of Flexner  organisms.  The  cross- 
agglutination reactions of one of the more potent sera are given in Table III. 
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Type V specific antigen agglutinates not only the homologous organisms but 
those  of  heterologous  strains  as  well.  The  cross-reactions  are  similar  to 
those  exhibited  by the serum of rabbits immunized with Type V organisms 
as indicated in Table IV. 
TABLE II 
Distribution of tke Increase in Specific Agglutinins Following Inoculation with Specific Antigen 
of  Type  V  Skigella  paradysenteriae (Flexner) 
Group 
I 
II 
III 
No.  of 
subjects 
8 
6 
Increase in agglutinins 
0  i  }.-,old  I.old  I  ,6-,old  I  S -,old 
No. of subjects 
2  I 
2 
1  ~. 
Average lncrease 
in agglutinins 
for each group 
5-fold 
16-fold 
-  H-fold 
TABLE III 
Homologous and Hetevologous Agglutinins in the Serum of a Subject Inoculated with the Specific 
Antigen of Type V Shigdla paradysenteriae (Flexner) 
Serum 
Post-treatment  ...... 
Pre-treatment  ....... 
suspT~nStsion 
',i 
V  4 
W  2 
X  3 
Y  4 
Z  4 
VZ  4 
V 
W 
X 
Y 
Z 
VZ 
Final dilution of serum 
1:50  I 
4 
1 
2 
4 
4 
4 
2 
0 
1 
3 
0 
0 
100  I:  200 
4  4 
1  0 
i  ½ 
4  4 
4  4 
4  4 
0 
0  0 
½  o 
0  0 
0  0 
0  0 
1:400  1:800  1:1600 
Mouse Protection Tests (Homologous).--For purposes of determining the average increase 
in mouse-protective antibodies the sera of the individuals before and after injection of the 
specific antigen were in each instance pooled.  The  tests were performed with a  mouse- 
virulent Type V strain.  Varying concentrations of serum were injected subcutaneously into 
mice  18  hours before the  intraperitoneal injection of  the  challenging dose of organisms. 
The bacteria were obtained from a  6 hour culture and were thoroughly mixed with a sterile 
5 per cent suspension of Wilson's granular mucin Type 1701-W  (25).  The challenging dose 
consisted of 5400 organisms, representing more than 1500 Z~.L.D.  The 50 per cent survival 
end point was determined by the method of Reed and Muench (26). E. PERLMAN~ F. BINKLEY, AND W. i~. GOEBEL  353 
The results  of the protection  tests given in Table V  indicate  that a  tenfold 
increase  in  mouse-protective  antibodies  can  be  demonstrated  in  the  pooled 
TABLE IV 
Homologous and  Heterologous A gglutinins in Serum  of a Rabbit Injected witk Heat-Killed 
Type  V  Skigella paradysenteriae (Flexner) Organisms 
Test  Final dilution of serum 
suspension 
1:50  1:100  1:400  1:800  1:1600 
type 
V 
W 
X 
¥ 
Z 
VZ 
)0  1:200 
3 
1 
0 
2 
2 
3 
1:,  00  1:6400 
0 
0 
0 
0 
0 
0 
TABLE V 
Homologous Protective Antibodies in Pooled Sera of Individuals  before and afler lnoculaaon 
with Type V Antigen 
Serum 
Pooled pre-treatment 
Pooled post-treatment 
None 
Amount used 
6C. 
0.05 
0.10 
0.20 
0.30 
0.40 
0.005 
0.010 
0.020 
0.040 
0.060 
No. of mice 
Survived*  Died 
0  4 
0  4 
2  2 
4  0 
4  0 
0  4 
0  4 
2  2 
4  0 
4  0 
0  3 
50  per  cent 
end  point 
0.20 
0.02 
Challenging dose of organisms: 0.05 cc. of a  10  ~  dilution of culture 
5400 organisms =  >  1500 X~.L.D. 
M.L.9.:  3 organisms in mucin killed all control mice injected. 
* Survived more than 5 days. 
+  0.95 cc. mucin - 
sera  of  the  immunized  subjects.  This  increase  corresponds  well  with  the 
increase  in  agglutinin  titer  of  the  pooled  sera. 
Mouse Protection  Tests  (Heterologous).--The  capacity  of  the  pooled  sera  to 
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organism was likewise determined.  Since the Type Z  strain was not as viru- 
lent as  the  Type V,  the  challenging dose  of  organisms  (40,000  bacilli) was 
133 Lb. 5o.  The results presented in Table VI indicate that there is a  twofold 
increase in heterologous Type  Z  mouse-protective antibodies in the  sera  of 
the  inoculated individuals. 
Injection of Specific Polysaccharide.--In  addition to the specific antigen the 
fractionation of  extracts  of  the  Type  V  Flexner organisms yields a  specific 
TABLE VI 
Heterologous Protective Antibodies in Pooled Sera of IndCviduals before and after lnoculation 
with Type V Antigen 
Serum 
Pooled pre-treatment 
Pooled post-treatment 
None 
Amount used 
CC. 
0.20 
0.24 
0.28 
0.32 
0.36 
0.10 
0.14 
0.18 
0.22 
0.26 
No. of mice 
Survived*  Died 
0  4 
0  4 
2  2 
2  2 
4  0 
0  4 
1  3 
4  0 
4  0 
4  0 
0  3 
50 per cent 
end  point 
0.296 
0.156 
Challenging dose of organisms: 0.5 cc. of a 10  --4 dilution of culture +  0.5 cc. mucincon- 
raining 40,000 organisms equivalent to approximately  133 L.D.s0. 
L.D.S,: approximately 300 organisms. 
* Survived more than 5 days. 
polysaccharide.  This  preparation  is  not  toxic  whert  injected  into  mice  in 
quantities as  great as 20 mg.  Although this material does not stimulate the 
production of antibodies in rabbits, it was tested in a group of human volunteers 
in order to determine whether, like the pneumococcal polysaccharides (27-29) 
it would be antigenic in man. 
Ten volunteers were divided into 3 groups as indicated  below.  Single  intracutaneous 
injections were given, except to the subjects  in group IIL  These individuals received  2 
injections administered 1 week apart. 
Group I:  Group II:  Group III: 
4 subjects  3 subjects  3 subjects 
Dose  50 ug.  100 ~g.  100 ~g. 
I00  " 
Total .............................................................  200 ~g. E. PERLMAN~  ~. BINKLEY, AND W. F. GOEBEL  355 
All individuals were bled before and 3 weeks following the inoculation.  In 
no  case  was there  a  systemic reaction.  The  local reactions  were  mild,  con- 
sisting  of slight swelling and erythema which reached a  diameter  not greater 
than  1.5  cm.  There  was  no  adenopathy  or  lymphangitis.  Two  of  the  10 
subjects  developed agglutinins;  one had  received  50 #g. and  the other 100#g. 
of polysaccharide.  The former subject showed a  sixteenfold increase and the 
latter a  fourfold increase in homologous agglutinins.  The more potent serum 
was tested for mouse-protective antibodies against the Type V organism.  The 
protocol is given in Table VII. 
TABLE VII 
Mouse-Protective Test of Serum of a Subject Inoculated with Specific Polysaccharide of Type V 
Shigella paradysenteriae (Flexner) 
Serum ofsubject  Sc 
're-treatment 
'ost-treatment 
Tone 
Amount  used 
CO. 
0.05 
0.10 
0.20 
0.30 
0.01 
0.02 
0.03 
0.04 
No. of mice 
Survived*  Died 
0  3 
2  1 
3  0 
3  0 
0  3 
0  3 
1  2 
3  0 
0  3 
"50per cent 
end point 
CO. 
0.090 
0.032 
Challenging dose of organisms: 0.05 cc. of a 10  -~ dilution of culture 
3000 organisms =  >  1500 M.L.D. 
~.L.D.: 3 organisms in mucin killed all mice injected. 
* Survived more than 5 days. 
+  0.95 cc. mucin  = 
It  can  be  seen  from Table  VII that  the  injection  of the  Type  V  specific 
polysaccharide  produced  a  threefold  increase in homologous mouse-protective 
antibodies  in the serum of one of the subjects. 
DISCUSSION 
The use of immunologically active and antigenic bacterial products for the 
experimental  immunization of man has been reported by a  number of investi- 
gators.  The protein-free  capular polysaccharides of Pneumococcus appear to 
function well in the production of specific antibodies when administered  intra- 
dermally to human beings in minute amounts  (27-29).  The somatic antigens 
of the typhoid (12) and Shiga dysentery bacillus (13) have likewise been found 
to  evoke  specific  agglutinating  and  mouse-protective  antibodies  in  human 356  FLEXIVER GROUP  OF DYSENTERY  BACILLI.  ILl 
subjects.  Indeed, in one well established  study (30, 31), it was shown that a 
marked lowering in morbidity and mortality in a  large  group of individuals 
resulted from the injection of an extract containing the endotoxin of Eber- 
thella typhosa.  In all these studies it has been the objective  of these investi- 
gators to avoid the severe and toxic  reactions  which  accompany the use  of 
whole  vaccines.  Save  in  the  case of  the  pneumococcal  polysaccharides  it 
cannot be said that this objective has been reached, for toxicity is an inherent 
property of the  somatic antigens of all  the  Gram-negative organisms  that 
have been investigated. 
Although it has been possible to demonstrate a  correlation  between agglu- 
tinins, mouse-protective  antibodies,  and actual immunity in certain infectious 
diseases, it has thus far not been  demonstrated for bacillary dysentery.  In 
the latter disease the organisms are confined to the gastrointestinal tract and 
only rarely  cause  bacteremia.  It  would  seem,  therefore,  that  circulating 
antibodies do not necessarily reflect the state of local tissue immunity in the 
gastrointestinal tract (32).  In spite  of numerous attempts to determine the 
efficacy  of  vaccination  against  the  Flexner  dysentery bacilli,  considerable 
confusion and differences of opinion have resulted.  Indeed, it has not been 
fully determined whether an actual attack of bacillary dysentery confers any 
immunity to subsequent  infection (33-35).  However, evidence gathered from 
carefully controlled bacteriological and epidemiological studies seems to support 
the view that an attack of dysentery does confer an active immunity against 
subsequent  infections  with  bacilli  of  the  homologous  type.  That  Flexner 
dysentery vaccines may have prophylactic value is also suggested by a recent 
study of their use in the control of institutional dysentery (36). 
In the foregoing account the experimental inoculation of human subjects 
with the specific somatic antigen of Type V Flexner dysentery bacillus has 
been  described.  This  purified  material,  free  from  contaminating  cellular 
constituents, gives rise to reactions in human beings which are no more severe 
than those  described  in  connection  with typhoid-paratyphoid vaccines.  In 
response to the inoculations  of the antigen the individuals developed  specific 
bacterial  agglutinins,  and  mouse-protective  antibodies  as  well.  Subjects 
injected with the specific antigen of the Type V bacillus developed a high titer 
of agglutinins which diminished  moderately after a period  of 6 months.  At 
this time the titer of circulating  antibodies can be increased by a small recall 
dose.  Therefore,  if agglutinins in any way reflect immunity, the duration of 
the effect is sufficient to be of practical value. 
One of the factors which must be taken into consideration  in the develop- 
ment of an effective immunizing agent is the multiplicity of species and types 
involved  in the etiology of bacillary dysentery.  In the present study it has 
been  shown  that immunization with the specific antigen of Type V evokes 
agglutinins which cross-react with other organisms of the Flexner group.  In E. PERLMAN,  F. BINKLEY~  AND W. F. GOEBEL  357 
the sera of the vaccinated individuals it has also been possible to demonstrate 
the presence of antibodies capable of protecting mice against infection with a 
cross-reacting Type Z strain.  It may be pointed out that the V, Z, VZ, and 
Y  types of Shigella paradysenteriae (Flexner) are intimately interrelated sero- 
logically (36,  16).  With this in mind and with a  knowledge of the relative 
frequency of the etiological agents in bacillary dysentery it would seem that a 
mixed antigen containing Types V and W  Shigdla paradysenteriae (Flexner), 
Shigella sp.  Newcastle and sp.  Sonn~ antigens would anticipate  the greatest 
number of infections. 
The specific polysaccharide of the Type V Shigella paradysenteriae (Flexner) 
when injected into a number of volunteers gave rise in one instance to mouse- 
protective antibodies.  Thus, it appears that antibodies directed against this 
one portion of the antigenic complex are capable of protecting mice from lethal 
infection  with  the  homologous  organisms.  Although  the  response  to  the 
injection of the polysaccharide is irregular and uncertain, the results suggest 
that the toxic portion of the full antigen may not be necessary for the pro- 
duction  of prophylactic immunity.  The  carbohydrate used  in  the  present 
study was obtained by fractionating a  crude extract of the organisms.  There 
is some evidence that this preparation  is partially depolymerized.  A  poly- 
saccharide  subsequently obtained  by  chemical degradation of  the  antigenic 
complex was found to be more active immunologically and was likewise non- 
toxic.  Future tests with this more active preparation, it is hoped, may prove 
it to be more consistent and reliable as a  non-toxic antigen in human beings. 
SUMMARY 
1.  Volunteers have  been  immunized with  the  purified  specific  antigen of 
Type  V  Shigdla  paradysenteriae  (Flexner).  The  subjects  developed  a  high 
titer  of bacterial  agglutinins and  mouse-protective  antibodies.  The  agglu- 
finin fiter fell moderately after a period of 6 months.  The subjects responded 
fairly well to a  small recall dose of the antigen. 
2.  Two individuals from a  group of 10 injected with the specific  polysac- 
charide obtained from Type V organisms responded with an increase in bacte- 
rial agglutinins.  Mouse-protective antibodies  were  demonstrable in the one 
serum tested. 
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